Idelalisib Adverse Event Report 2018


This report includes data from the FDA’s Adverse Events Reports for 2018.  We removed reports where the subject of the report was taking only this drug. This report provides the following fields:

  • ID
  • Patient Summary
  • Patient Gender
  • Patient Age
  • Drug Products
  • Drug Reactions


Idelalisib is used together with rituximab (Rituxan) to treat chronic lymphocytic leukemia, and certain types of lymphoma. Idelalisib is given after other cancer treatments did not work or have stopped working. Idelalisib was approved by the US Food and Drug Administration (FDA) on an “accelerated” basis. In clinical studies, some people responded to idelalisib, but further studies are needed. Idelalisib may also be used for purposes not listed in this medication guide.